Edward B. Garon, MD, MS | Authors

February 03, 2023

In the third installment of this series, Edward B. Garon, MD, MS, gives a historical overview of first-line immunotherapy options for non–small cell lung cancer, discusses the recent FDA approval of durvalumab/tremelimumab in combination with platinum-based chemotherapy in the same setting, and assesses treatment and research goals in the field.

December 20, 2022

In the second installment of this series, Edward B. Garon, MD, MS, explains the rationale for using combination IO therapies alongside chemotherapy for first-line treatment of metastatic non-small cell lung cancer (NSCLC), discusses key data from the POSEIDON trial presented at recent meetings, and elaborates on how these regimens may change his clinical practice.

December 02, 2022

Edward B. Garon, MD, MS, provides an overview of the phase 3 CANOPY-A study.

November 15, 2022

A lung cancer expert describes the common adverse events he sees with immunotherapy in mNSCLC, and the available management strategies.

November 15, 2022

Edward B. Garon, MD, MS, shares his biomarker testing protocols for patients with NSCLC and highlights the most important biomarkers for guiding therapy.

November 15, 2022

Dr Edward B. Garon explains the rationale for treating patients with mNSCLC with a frontline combination of chemotherapy and immune checkpoint inhibitors.